WeVote

Bill

Bill

HB 2283

Relating to the use of an epinephrine delivery device by certain entities.

89th Legislature (2025) Introduced by Philip Cortez and 1 co-sponsor

HB 2283 permits schools, workplaces, and public venues to stock and use epinephrine auto-injectors for emergency allergic reaction treatment without on-site medical supervision.

Left pending in committee
0
WeVote Research Nonpartisan
Bill Summary · HB 2283

Legislative bill overview

HB 2283 expands authorization for certain non-medical entities to possess and deploy epinephrine auto-injectors (EpiPens) to treat severe allergic reactions. The bill clarifies which organizations—likely including schools, workplaces, and public venues—can stock and use these life-saving devices without requiring on-site medical professionals.

Why is this important

Epinephrine is the only effective first-line treatment for anaphylaxis, a severe allergic reaction that can be fatal within minutes. Expanding access to epinephrine delivery devices in public spaces increases survival rates for people experiencing allergic emergencies, particularly children in schools who may not have immediate access to medical care.

Potential points of contention

  • Liability concerns: Organizations may face uncertainty about legal responsibility if epinephrine is administered incorrectly or if complications occur, despite good-faith emergency response
  • Training and storage requirements: The bill may lack specificity on who trains staff to recognize anaphylaxis and properly administer epinephrine, or how devices should be maintained and replaced
  • Equitable access: Coverage may be uneven across schools and public facilities, potentially creating disparities in emergency preparedness between well-funded and under-resourced communities

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.